Quick Answer
BioAtla, Inc. reported Operating Income Loss of -$59.31 million for the year ending 2025.
- BioAtla, Inc. showed an increase of +19.8% in Operating Income Loss from 2024 to 2025.
- This data is from BioAtla, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.11 million | Q2 2020: -$4.52 million | Q3 2020: -$8.02 million | Q1 2021: -$18.80 million | Q2 2021: -$30.46 million | Q3 2021: -$23.70 million | Q1 2022: -$24.35 million | Q2 2022: -$29.06 million | Q3 2022: -$26.18 million | Q1 2023: -$28.93 million | Q2 2023: -$37.20 million | Q3 2023: -$35.02 million | Q1 2024: -$24.46 million | Q2 2024: -$21.97 million | Q3 2024: -$11.27 million | Q1 2025: -$17.61 million | Q2 2025: -$18.65 million | Q3 2025: -$13.79 million.
- Over the full 7 years of available data (2019 to 2025), BioAtla, Inc.'s Operating Income Loss has declined by 109.8%.
- Historical annual values: Fiscal year 2025: -$59.31 million | Fiscal year 2024: -$73.94 million | Fiscal year 2023: -$129.69 million | Fiscal year 2022: -$108.14 million | Fiscal year 2021: -$96.44 million | Fiscal year 2020: -$30.10 million | Fiscal year 2019: -$28.27 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: